# A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

> **NCT02754882** · PHASE3 · COMPLETED · sponsor: **Samsung Bioepis Co., Ltd.** · enrollment: 763 (actual)

## Conditions studied

- Lung Cancer
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** SB8
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02754882
- **Lead sponsor:** Samsung Bioepis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-05
- **Primary completion:** 2018-01-24
- **Final completion:** 2018-10-09
- **Target enrollment:** 763 (ACTUAL)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02754882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02754882, "A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02754882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*